Nifty
Sensex
:
:
25461.00
83432.89
55.70 (0.22%)
193.42 (0.23%)

Pharmaceuticals & Drugs - API

Rating :
62/99

BSE: 500288 | NSE: MOREPENLAB

65.36
04-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  64.05
  •  66
  •  63.54
  •  63.94
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  9454752
  •  614267777.08
  •  100.9
  •  42

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,574.85
  • 29.69
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,604.88
  • 0.31%
  • 3.03

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 35.65%
  • 2.41%
  • 48.75%
  • FII
  • DII
  • Others
  • 1.94%
  • 0.95%
  • 10.30%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.48
  • 14.66
  • 3.00

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.64
  • 18.28
  • 3.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 46.30
  • 23.42
  • -1.84

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.13
  • 27.94
  • 31.43

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.79
  • 3.50
  • 2.76

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.71
  • 16.44
  • 17.21

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
1.88
2.2
P/E Ratio
34.77
29.71
Revenue
1682
1812
EBITDA
159
174
Net Income
96
118
ROA
8
7.7
P/B Ratio
3.76
3.10
ROE
12.02
11.78
FCFF
2
-100
FCFF Yield
0.06
-2.79
Net Debt
-23
-22
BVPS
17.39
21.1

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
465.85
423.07
10.11%
452.78
444.55
1.85%
437.73
421.77
3.78%
455.22
401.04
13.51%
Expenses
423.61
374.69
13.06%
416.64
393.99
5.75%
393.66
388.18
1.41%
403.60
374.95
7.64%
EBITDA
42.24
48.38
-12.69%
36.14
50.57
-28.53%
44.07
33.59
31.20%
51.62
26.09
97.85%
EBIDTM
9.07%
11.44%
7.98%
11.37%
10.07%
7.96%
11.34%
6.51%
Other Income
4.61
4.24
8.73%
5.34
4.07
31.20%
4.99
3.24
54.01%
3.43
2.42
41.74%
Interest
4.67
0.80
483.75%
1.34
2.17
-38.25%
1.18
0.46
156.52%
1.15
0.28
310.71%
Depreciation
16.47
9.62
71.21%
4.93
8.45
-41.66%
1.86
7.69
-75.81%
5.73
7.71
-25.68%
PBT
25.71
42.20
-39.08%
35.20
44.02
-20.04%
46.02
28.68
60.46%
48.17
20.51
134.86%
Tax
5.40
13.46
-59.88%
8.52
12.03
-29.18%
11.17
7.43
50.34%
12.00
5.88
104.08%
PAT
20.31
28.74
-29.33%
26.69
31.99
-16.57%
34.85
21.26
63.92%
36.17
14.63
147.23%
PATM
4.36%
6.79%
5.89%
7.20%
7.96%
5.04%
7.95%
3.65%
EPS
0.37
0.55
-32.73%
0.49
0.63
-22.22%
0.64
0.42
52.38%
0.71
0.29
144.83%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
1,811.58
1,690.43
1,417.53
1,546.83
1,188.06
853.07
768.54
606.51
595.47
485.08
400.64
Net Sales Growth
7.17%
19.25%
-8.36%
30.20%
39.27%
11.00%
26.72%
1.85%
22.76%
21.08%
 
Cost Of Goods Sold
1,159.31
1,016.87
900.22
980.35
735.29
524.19
479.12
361.28
358.35
293.33
238.62
Gross Profit
652.27
673.56
517.31
566.47
452.77
328.87
289.42
245.23
237.12
191.76
162.02
GP Margin
36.01%
39.85%
36.49%
36.62%
38.11%
38.55%
37.66%
40.43%
39.82%
39.53%
40.44%
Total Expenditure
1,637.51
1,531.81
1,338.00
1,410.15
1,069.54
784.55
701.02
541.78
534.09
423.52
352.41
Power & Fuel Cost
-
34.09
23.78
18.93
13.00
12.56
13.18
11.08
9.84
7.64
7.41
% Of Sales
-
2.02%
1.68%
1.22%
1.09%
1.47%
1.71%
1.83%
1.65%
1.57%
1.85%
Employee Cost
-
181.47
154.68
164.25
135.59
109.91
95.36
76.53
69.69
58.29
48.79
% Of Sales
-
10.74%
10.91%
10.62%
11.41%
12.88%
12.41%
12.62%
11.70%
12.02%
12.18%
Manufacturing Exp.
-
95.75
91.70
98.99
67.21
48.92
31.28
16.21
22.36
13.33
12.68
% Of Sales
-
5.66%
6.47%
6.40%
5.66%
5.73%
4.07%
2.67%
3.76%
2.75%
3.16%
General & Admin Exp.
-
66.63
55.44
42.38
34.71
36.47
36.14
28.52
18.11
18.14
15.89
% Of Sales
-
3.94%
3.91%
2.74%
2.92%
4.28%
4.70%
4.70%
3.04%
3.74%
3.97%
Selling & Distn. Exp.
-
109.98
93.01
53.58
49.66
40.11
32.73
30.04
25.79
23.45
21.40
% Of Sales
-
6.51%
6.56%
3.46%
4.18%
4.70%
4.26%
4.95%
4.33%
4.83%
5.34%
Miscellaneous Exp.
-
27.02
19.17
51.67
34.08
12.39
13.20
18.11
29.95
9.35
21.40
% Of Sales
-
1.60%
1.35%
3.34%
2.87%
1.45%
1.72%
2.99%
5.03%
1.93%
1.90%
EBITDA
174.07
158.62
79.53
136.68
118.52
68.52
67.52
64.73
61.38
61.56
48.23
EBITDA Margin
9.61%
9.38%
5.61%
8.84%
9.98%
8.03%
8.79%
10.67%
10.31%
12.69%
12.04%
Other Income
18.37
13.97
6.13
20.10
12.07
9.48
3.67
3.72
3.72
1.20
1.37
Interest
8.34
3.71
1.98
2.43
1.79
1.98
2.11
4.36
7.56
10.50
8.66
Depreciation
28.99
33.47
27.93
27.64
30.28
36.91
39.90
34.32
33.90
35.20
38.67
PBT
155.10
135.42
55.76
126.70
98.51
39.11
29.18
29.77
23.63
17.06
2.28
Tax
37.09
38.80
17.08
25.02
1.42
5.53
0.34
0.00
0.00
-0.13
0.14
Tax Rate
23.91%
28.65%
30.63%
19.75%
1.44%
14.14%
1.17%
0.00%
0.00%
-1.03%
6.14%
PAT
118.02
96.16
38.68
101.68
97.09
33.58
28.85
29.59
23.63
12.80
2.14
PAT before Minority Interest
118.02
96.62
38.68
101.68
97.09
33.58
28.84
29.77
23.63
12.80
2.14
Minority Interest
0.00
-0.46
0.00
0.00
0.00
0.00
0.01
-0.18
0.00
0.00
0.00
PAT Margin
6.51%
5.69%
2.73%
6.57%
8.17%
3.94%
3.75%
4.88%
3.97%
2.64%
0.53%
PAT Growth
22.15%
148.60%
-61.96%
4.73%
189.13%
16.40%
-2.50%
25.22%
84.61%
498.13%
 
EPS
2.15
1.75
0.71
1.86
1.77
0.61
0.53
0.54
0.43
0.23
0.04

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
847.23
752.91
578.56
424.75
284.06
253.09
225.94
196.26
300.28
287.48
Share Capital
102.23
102.23
95.56
89.96
89.96
89.96
89.96
89.96
209.61
209.61
Total Reserves
745.00
650.68
456.75
291.04
194.10
163.13
135.98
106.30
90.67
77.87
Non-Current Liabilities
43.93
36.88
35.50
30.06
28.42
23.38
20.20
17.80
57.47
74.00
Secured Loans
3.36
0.93
1.32
0.83
0.92
1.83
2.95
1.38
43.41
62.27
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
33.82
29.74
28.24
25.39
23.82
19.01
14.42
13.59
11.34
9.22
Current Liabilities
402.04
321.16
456.46
403.80
351.44
339.17
340.12
324.86
166.56
127.92
Trade Payables
295.03
226.88
258.12
208.85
172.30
168.15
174.88
124.88
115.33
84.96
Other Current Liabilities
58.51
54.86
169.97
174.38
165.06
160.64
163.90
198.65
47.04
39.87
Short Term Borrowings
23.49
23.18
16.13
15.32
11.36
8.99
0.00
0.00
0.00
2.23
Short Term Provisions
25.02
16.24
12.24
5.25
2.72
1.39
1.33
1.33
4.19
0.86
Total Liabilities
1,293.20
1,110.49
1,070.06
858.15
663.46
615.18
585.81
538.29
523.68
489.00
Net Block
307.35
266.97
251.80
224.52
216.37
236.21
264.29
271.80
296.72
322.48
Gross Block
620.63
656.24
613.25
628.32
752.55
887.76
997.60
1,026.96
1,018.43
1,009.35
Accumulated Depreciation
313.28
389.27
361.45
403.79
536.18
651.55
733.31
755.15
721.72
686.87
Non Current Assets
404.16
354.33
335.75
331.36
291.29
315.71
342.37
346.34
366.53
374.42
Capital Work in Progress
24.45
17.01
14.15
1.96
0.00
0.00
0.00
0.00
0.00
0.00
Non Current Investment
1.30
0.00
0.00
1.08
1.08
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
70.82
70.07
69.53
103.52
73.55
79.22
77.81
73.69
69.82
51.94
Other Non Current Assets
0.24
0.28
0.28
0.27
0.28
0.28
0.27
0.85
0.00
0.00
Current Assets
889.04
756.16
734.30
526.79
372.18
299.47
243.44
191.95
157.15
114.58
Current Investments
0.00
0.00
0.00
0.00
0.00
0.02
0.22
0.00
0.00
0.00
Inventories
248.59
228.89
275.85
175.33
138.48
94.20
76.89
64.66
42.14
37.11
Sundry Debtors
324.94
263.25
250.64
181.98
137.68
133.75
121.85
92.95
87.94
56.14
Cash & Bank
52.12
56.31
45.97
67.89
38.88
32.21
5.95
7.59
4.36
8.85
Other Current Assets
263.40
7.15
5.29
10.01
57.14
39.29
38.54
26.74
22.71
12.48
Short Term Loans & Adv.
246.96
200.58
156.54
91.58
51.16
31.43
32.92
22.03
16.77
9.34
Net Current Assets
487.00
435.00
277.84
122.99
20.73
-39.70
-96.68
-132.92
-9.41
-13.34
Total Assets
1,293.20
1,110.49
1,070.05
858.15
663.47
615.18
585.81
538.29
523.68
489.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
73.37
-91.17
-60.24
50.83
11.02
17.37
63.41
40.73
50.07
50.70
PBT
135.42
55.76
126.70
98.51
39.11
29.18
29.77
23.04
17.06
2.28
Adjustment
34.20
27.90
19.46
31.96
36.63
40.32
38.64
41.40
45.69
47.32
Changes in Working Capital
-58.12
-158.28
-181.47
-78.18
-58.84
-51.78
-5.00
-23.72
-8.41
1.23
Cash after chg. in Working capital
111.49
-74.62
-35.31
52.29
16.89
17.71
63.41
40.73
54.34
50.83
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-38.12
-16.55
-24.93
-1.46
-5.88
-0.34
0.00
0.00
0.13
-0.13
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-4.40
0.00
Cash From Investing Activity
-83.30
-46.51
-31.68
-70.35
-12.46
-13.05
-26.93
-13.60
-27.30
-31.65
Net Fixed Assets
27.27
-35.47
24.52
123.41
135.60
113.16
31.96
-8.08
-7.02
-4.73
Net Investments
-8.34
-0.05
0.99
0.00
-1.07
0.20
-0.22
0.00
0.25
0.00
Others
-102.23
-10.99
-57.19
-193.76
-146.99
-126.41
-58.67
-5.52
-20.53
-26.92
Cash from Financing Activity
5.20
143.54
66.33
47.27
5.49
-0.44
-37.77
-23.72
-27.26
-19.31
Net Cash Inflow / Outflow
-4.72
5.86
-25.58
27.75
4.04
3.88
-1.29
3.40
-4.49
-0.26
Opening Cash & Equivalents
21.67
15.80
41.39
13.64
9.60
5.72
7.00
3.60
8.85
9.11
Closing Cash & Equivalent
16.95
21.67
15.80
41.39
13.64
9.60
5.72
7.00
4.36
8.85

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
16.58
14.73
11.56
8.47
6.32
5.63
5.02
4.36
4.02
3.73
ROA
8.04%
3.55%
10.55%
12.76%
5.25%
4.80%
5.30%
4.45%
2.53%
0.44%
ROE
12.08%
5.93%
21.79%
29.20%
12.50%
12.04%
14.10%
12.54%
7.35%
1.24%
ROCE
16.82%
8.40%
24.86%
27.13%
12.05%
10.01%
14.05%
10.18%
6.29%
2.90%
Fixed Asset Turnover
2.65
2.23
2.49
1.72
1.04
0.82
0.60
0.58
0.49
0.41
Receivable days
63.50
66.16
51.04
49.10
58.07
60.70
64.63
55.44
53.22
44.17
Inventory Days
51.55
64.98
53.23
48.20
49.78
40.63
42.59
32.73
29.27
31.48
Payable days
93.67
98.32
86.93
94.60
79.06
88.85
103.38
82.97
83.88
76.01
Cash Conversion Cycle
21.38
32.82
17.35
2.71
28.78
12.48
3.85
5.20
-1.39
-0.36
Total Debt/Equity
0.03
0.03
0.03
0.04
0.05
0.52
0.06
0.25
0.22
0.28
Interest Cover
37.50
29.15
53.22
56.09
20.71
14.83
7.83
4.13
2.21
1.26

News Update:


  • Morepen Laboratories incorporates wholly owned subsidiary in Dubai
    19th Jun 2025, 10:52 AM

    The said WOS has been incorporated for trading in pharmaceuticals/ medicines (outside UAE)

    Read More
  • Morepen Laboratories reports 29% fall in Q4 consolidated net profit
    13th May 2025, 12:29 PM

    The total consolidated income of the company increased by 10.10% at Rs 470.46 crore for Q4FY25

    Read More
  • Morepen Laboratories to launch new drug for Fatty Liver
    29th Apr 2025, 12:50 PM

    The company has received clearance from Subject Expert Committee of CDSCO to conduct Bioequivalence studies for Resmetirom 60 mg, 80 mg and 100 mg tablets

    Read More
  • Morepen Laboratories gets nod to incorporate wholly owned subsidiary in Dubai
    29th Apr 2025, 10:09 AM

    The Finance Committee of the Board of Directors of the Company, at its meeting held on April 28, 2025 has approved the same

    Read More
  • Morepen Laboratories secures Loratadine approval for export to China
    1st Apr 2025, 09:50 AM

    This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.